These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 29354490)

  • 21. [Can the combination of bladder ultrasonography and urinary cytodiagnosis replace cystoscopy in the diagnosis and follow-up of tumors of the bladder?].
    Cariou G; Maaraoui N; Cortesse A
    Prog Urol; 1997 Feb; 7(1):51-5. PubMed ID: 9116739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary markers in the everyday diagnosis of bladder cancer.
    Dal Moro F; Valotto C; Guttilla A; Zattoni F
    Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of urothelial carcinoma, upper tract urothelial carcinoma, bladder carcinoma, and urothelial carcinoma with gross hematuria using selected urine-DNA methylation biomarkers: A prospective, single-center study.
    Guo RQ; Xiong GY; Yang KW; Zhang L; He SM; Gong YQ; He Q; Li XY; Wang ZC; Bao ZQ; Li XS; Zhang K; Zhou LQ
    Urol Oncol; 2018 Jul; 36(7):342.e15-342.e23. PubMed ID: 29706459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urine cytology and adjunct markers for detection and surveillance of bladder cancer.
    Sullivan PS; Chan JB; Levin MR; Rao J
    Am J Transl Res; 2010 Jul; 2(4):412-40. PubMed ID: 20733951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of semaphorin 3A in patients with urothelial cancer.
    Vadasz Z; Rubinstein J; Bejar J; Sheffer H; Halachmi S
    Urol Oncol; 2018 Apr; 36(4):161.e1-161.e6. PubMed ID: 29288007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer.
    Yafi FA; Brimo F; Auger M; Aprikian A; Tanguay S; Kassouf W
    Urol Oncol; 2014 Jan; 32(1):27.e1-6. PubMed ID: 23410943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene-based urinary biomarkers for bladder cancer: an unfulfilled promise?
    Sapre N; Anderson PD; Costello AJ; Hovens CM; Corcoran NM
    Urol Oncol; 2014 Jan; 32(1):48.e9-17. PubMed ID: 24140246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostics techniques in nonmuscle invasive bladder cancer.
    Soubra A; Risk MC
    Indian J Urol; 2015; 31(4):283-8. PubMed ID: 26604438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Non-invasive urinary diagnosis of bladder cancer. What do we know?].
    Kausch I; Böhle A
    Urologe A; 2003 Jul; 42(7):912-21. PubMed ID: 12898034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NMP-22, urinary cytology, and cystoscopy: a 1 year comparison study.
    Schlake A; Crispen PL; Cap AP; Atkinson T; Davenport D; Preston DM
    Can J Urol; 2012 Aug; 19(4):6345-50. PubMed ID: 22892257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer.
    Karnwal A; Venegas R; Shuch B; Bassett J; Rajfer J; Reznichek R
    Can J Urol; 2010 Apr; 17(2):5077-81. PubMed ID: 20398445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection.
    Wallace E; Higuchi R; Satya M; McCann L; Sin MLY; Bridge JA; Wei H; Zhang J; Wong E; Hiar A; Mach KE; Scherr D; Egerdie RB; Ohta S; Sexton WJ; Meng MV; Weizer AZ; Woods M; Jansz GK; Zadra J; Lotan Y; Goldfarb B; Liao JC
    J Urol; 2018 Mar; 199(3):655-662. PubMed ID: 29061538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bladder Cancer Diagnosis and Follow-Up: The Current Status and Possible Role of Extracellular Vesicles.
    Oeyen E; Hoekx L; De Wachter S; Baldewijns M; Ameye F; Mertens I
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30769831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urinary Protein Markers for the Detection and Prognostication of Urothelial Carcinoma.
    Szarvas T; Nyirády P; Ogawa O; Furuya H; Rosser CJ; Kobayashi T
    Methods Mol Biol; 2018; 1655():251-273. PubMed ID: 28889391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Novel Urine-Based Assay for Bladder Cancer Diagnosis: Multi-Institutional Validation Study.
    Davis N; Shtabsky A; Lew S; Rona R; Leibovitch I; Nativ O; Cohen M; Mor Y; Lindner U; Glickman Y; Matzkin H; Tsivian A; Gofrit O; Yossepovitch O
    Eur Urol Focus; 2018 Apr; 4(3):388-394. PubMed ID: 28753799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach.
    Lotan Y; Roehrborn CG
    J Urol; 2002 Jan; 167(1):75-9. PubMed ID: 11743279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alternatives to cytology in the management of non-muscle invasive bladder cancer.
    Amiel GE; Shu T; Lerner SP
    Curr Treat Options Oncol; 2004 Oct; 5(5):377-89. PubMed ID: 15341676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patients with a negative cystoscopy and negative Nmp22® Bladderchek® test are at low risk of missed transitional cell carcinoma of the bladder: a prospective evaluation.
    Terrell JD; Elias KJ; Sagalowsky AI; Lotan Y
    Int Braz J Urol; 2011; 37(6):706-11. PubMed ID: 22234001
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.